An Introduction to Real World Evidence Concepts, Insights, and Practical Application

• 4 Potential Uses for Improving Drug Development [Link] [LinkedIn]
• Purpose of Real World Evidence [Link] [LinkedIn]
• The Role of RWE in the Context of Digital Health [Link] [LinkedIn]
• What is the Connection between Real World Data (RWD) and Real World Evidence (RWE)? [Link] [LinkedIn]
• How Robust is RWE? [Link] [LinkedIn]
• Is Real World Evidence a Replacement for Clinical Trials? [Link] [LinkedIn]
• The Evolution of Real World Evidence Regulations [Link] [LinkedIn]
• Do I Need IRB Approval for My Observational Study? [Link] [LinkedIn]
• What is the Difference Between an IRB and a REC? [Link] [LinkedIn]
• Why is there so much excitement about the use of AI in the context of real world evidence? [Link] [LinkedIn]
• Secondary Use of Existing Data [Link] [LinkedIn]
• Primary Data versus Secondary Data [Link] [LinkedIn]
• Data Tokenization [Link] [LinkedIn]
• De-Identification versus Pseudo-Anonymisation [Link] [LinkedIn]
• The Impact of GDPR on RWE Research [Link] [LinkedIn]
• Ethical Foundation of RWE Research [Link] [LinkedIn]
• The Declaration of Helsinki [Link] [LinkedIn]
• Ethical Principles and Safeguards for Medical AI in the Context of Real World Evidence [Link] [LinkedIn]
• Is ICH GCP Applicable to Non-Interventional Studies? [Link] [LinkedIn]
• EMA Good Pharmacovigilance Practices (GVPs) [Link] [LinkedIn]
• ISPE GPP [Link] [LinkedIn]
• The Patient Voice [Link] [LinkedIn]
• Diversity [Link] [LinkedIn]
• Pregnancy Registries [Link] [LinkedIn]
• Registry vs Registry-Based Study [Link] [LinkedIn]
• DARWIN-EU [Link] [LinkedIn]
• The Impact of the EMAs Data Quality Framework on RWE [Link] [LinkedIn]
• The European Health Data Space (EHDS) [Link] [LinkedIn]
• Federated Clinical Data [Link] [LinkedIn]
• EHDS and GDPR – How does GDPR support the secondary use of existing health data for the purposes of scientific research? [Link] [LinkedIn]
• Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’? [Link] [LinkedIn]
• Acknowledgement of the Limitations of Clinical Trials and RWE Studies [Link] [LinkedIn]
• Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations [Link] [LinkedIn]
• Challenges in RWE Generation (Regulatory Grade RWE?) [Link] [LinkedIn]
• Verifying the Source of Data (Not to be Confused with Source Data Verification…Yup! Confusing!) [Link] [LinkedIn]
• The Role of RWE in Health Technology Assessments (HTAs) [Link] [LinkedIn]
• NICE Real World Evidence Framework [Link] [LinkedIn]
• Regulatory Science [Link] [LinkedIn]
• Regulatory Intelligence [Link] [LinkedIn]
• Regulatory Compliance [Link] [LinkedIn]
• The Importance of Regulatory Definitions [Link] [LinkedIn]
• Are the terms ‘clinical study’ and ‘clinical trial’ synonymous in the context of non-interventional studies? [Link] [LinkedIn]
• ‘Interventional’ Clinical Trial vs Non-Interventional Study [Link] [LinkedIn]
• Observational Studies vs Non-Interventional Studies [Link] [LinkedIn]

• NIS vs Market Research [Link] [LinkedIn]
• Postmarket Requirements (PMR) vs Post-Authorisation Safety Studies (PASS) [Link] [LinkedIn]
• Are Non-Interventional Studies Regulated? [Link] [LinkedIn]
• The Tuskegee Syphilis Study (the reason we have the Belmont Report and the Common Rule) [Link] [LinkedIn]
• The Tuskegee Syphilis Study – Supplement [Link] [LinkedIn]
• The Common Rule [Link] [LinkedIn]
• HIPAA [Link] [LinkedIn]
• Seeding Studies [Link] [LinkedIn]
• Why Should Non-Interventional Studies NOT be Promotional? [Link] [LinkedIn]
• Principles for Ensuring that Research Results are Reliable, Valid, and Objective [Link] [LinkedIn]
• Disease Prevalence vs Incidence [Link] [LinkedIn]
• Benefits of RWE in the Context of Rare Diseases [Link] [LinkedIn]
• Parkinson’s Disease [Link] [LinkedIn]
• How RWE is Being Used to Support the Treatment of Cancer [Link] [LinkedIn]
• Safety Monitoring [Link] [LinkedIn]
• Categories of PASS [Link] [LinkedIn]
• PASS Approval Requirements [Link] [LinkedIn]
• Protocol Considerations [Link] [LinkedIn]
• Study Designs [Link] [LinkedIn]
• Protocol Design and Scientific Best Practices [Link] [LinkedIn]
• Protocol Design and ISPE GPP [Link] [LinkedIn]
• STaRT-RWE [Link] [LinkedIn]
• HARPER [Link] [LinkedIn]
• Patient Recruitment [Link] [LinkedIn]
• Patient Retention [Link] [LinkedIn]
• Consent to Participate in Research vs Consent to Access and Process Sensitive Healthcare Data (GDPR) [Link] [LinkedIn]
• eConsent [Link] [LinkedIn]
• Monitoring [Link] [LinkedIn]
• Study Conduct [Link] [LinkedIn]
• ISF vs TMF [Link] [LinkedIn]
• TMF Reference Model versus the Real-World Study Document Index (RWS-DI) [Link] [LinkedIn]
• Study Close-Out [Link] [LinkedIn]
• Archiving Generics [Link] [LinkedIn]
• Archiving Specifics [Link] [LinkedIn]
• Publications [Link] [LinkedIn]
• Standard Operating Procedures [Link] [LinkedIn]
• SOPs and Regional Regulations [Link] [LinkedIn]
• Compliance Maps [Link] [LinkedIn]
• Audits [Link] [LinkedIn]
• Inspections [Link] [LinkedIn]
• Audits vs Inspections [Link] [LinkedIn]
• The Importance of Intent [Link] [LinkedIn]
• Ethical Imperatives [Link] [LinkedIn]
• Ethical Imperatives (CIOMS 2023) [Link] [LinkedIn]
• Project Managers [Link] [LinkedIn]
• Evolution of Regulatory Affairs [Link] [LinkedIn]
• RWE – A Career of Many Pathways [Link] [LinkedIn]
• ICH GCP (R3) – Real World Evidence Context [Link] [LinkedIn]